Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Phase II Study to Evaluate the Benefit of Chemotherapy Plus Best Supportive Care (BSC) Versus BSC in Patients With Metastatic Oesophageal Cancer of Squamous Cell-type Who Have Not Experienced a Disease Progression or Unacceptable Toxicity After a 6-weeks Chemotherapy Course .

NCT01248299 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT01248299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01248299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Phase II Study to Evaluate the Benefit of Chemotherapy Plus Best Supportive Care (BSC) Versus BSC in Patients With Metastatic Oesophageal Cancer of Squamous Cell-type Who Have Not Experienced a Disease Progression or Unacceptable Toxicity After a 6-weeks Chemotherapy Course .
Lead sponsor
Centre Oscar Lambret
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2011
Completion date
January 31, 2017
Enrollment
105 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of esophagus